Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

November 15, 2027

Study Completion Date

June 15, 2028

Conditions

Parkinson Disease

Interventions

BIOLOGICAL

ALC01 therapy

Bilateral implantation

Trial Locations (1)

Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

lead

iCamuno Biotherapeutics Ltd.

INDUSTRY